Pepcid AC Gelcaps Sample Pouch Deferral Granted Without "Drug Facts" Title
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck's request for a nine-month deferral from complying with the OTC labeling format for sample pouches of the company's H2 antagonist Pepcid AC Gelcaps has been granted.
You may also be interested in...
OTC Labeling Rule General Deferral For Convenience-Size Drugs To Be Issued
FDA will publish a notice to "delay the compliance date of the current Drug Facts rules with respect to 'convenience-size' drug packages" in an upcoming issue of the Federal Register
OTC Labeling Rule General Deferral For Convenience-Size Drugs To Be Issued
FDA will publish a notice to "delay the compliance date of the current Drug Facts rules with respect to 'convenience-size' drug packages" in an upcoming issue of the Federal Register
OTC Labeling Rule General Deferral For Convenience-Size Drugs To Be Issued
FDA will publish a notice to "delay the compliance date of the current Drug Facts rules with respect to 'convenience-size' drug packages" in an upcoming issue of the Federal Register